Business
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna (NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year, while the S&P 500 has gained 16%.
On Dec. 11, Pfizer (NYSE: PFE) and its German biotech partner BioNTech (NASDAQ: BNTX) became the…
-
General21 hours agoFootballers and movie stars: PM’s Shanghai tourism push
-
Business20 hours agoNvidia reaches the $4 trillion mark. Can it hit $5 trillion in 2025?
-
Business20 hours agoThis artificial intelligence (AI) and “Magnificent Seven” stock will be the next company to surpass a $3 trillion market cap by the end of 2025
-
General18 hours ago‘Hidden and radical’ power of First Nations women unlocked in big hART’s Punkaliyarra project